公开(公告)号：US20130231383A1

公开(公告)日：2013-09-05

申请号：US13821536

申请日：2011-09-21

申请人： Susumu Mitsutake ,  Kota Zama ,  Yasuyuki Igarashi ,  Tetsuya Yoshida ,  Yoshikazu Tanaka ,  Hiroshi Takemoto

发明人： Susumu Mitsutake ,  Kota Zama ,  Yasuyuki Igarashi ,  Tetsuya Yoshida ,  Yoshikazu Tanaka ,  Hiroshi Takemoto

IPC分类号： C12N15/113

CPC分类号： C12N15/1137 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/3231 ,  C12Y207/08

摘要： The problem of the present invention is to prove a medicament for decreasing body weigh, a medicament for decreasing visceral fat, a medicament for decreasing triglyceride in the liver, and a method for screening a medicament for ameliorating obesity and fatty liver. The problem is solved by a method comprising measuring an activity of a candidate material for inhibiting a sphingomyelin synthetase wherein if the candidate material has an activity for inhibiting a sphingomyelin synthetase, the candidate material is judged to have at least one function selected from the consisting of an anti-obesity drug, a drug for decreasing visceral fat, a drug for treating fatty liver and an agent for increasing adiponectin expression.

摘要翻译： 本发明的问题是证明减轻体重的药物，用于降低内脏脂肪的药物，用于降低肝脏中甘油三酯的药物，以及筛选用于改善肥胖症和脂肪肝的药物的方法。 该问题通过包括测定用于抑制鞘磷脂合成酶的候选材料的活性的方法来解决，其中如果候选物质具有抑制鞘磷脂合成酶的活性，则该候选物质被判断为具有至少一种选自以下的功能： 抗肥胖药，用于降低内脏脂肪的药物，用于治疗脂肪肝的药物和用于增加脂联素表达的药剂。

公开(公告)号：US20120315658A1

公开(公告)日：2012-12-13

申请号：US13498127

申请日：2010-09-22

申请人： Susumu Mitsutake ,  Yasuyuki Igarashi ,  Kota Zama ,  Tetsuya Yoshida ,  Yoshikazu Tanaka ,  Hiroshi Takemoto

发明人： Susumu Mitsutake ,  Yasuyuki Igarashi ,  Kota Zama ,  Tetsuya Yoshida ,  Yoshikazu Tanaka ,  Hiroshi Takemoto

IPC分类号： C12Q1/48 ,  C12N5/10

CPC分类号： C12Q1/48 ,  G01N2333/9129 ,  G01N2800/044

摘要： Disclosed is a method for screening for a medicinal agent that can decrease a body weight, a medicinal agent that can reduce a visceral fat, a medicinal agent that can reduce a triglyceride in the liver, and a medicinal agent that can ameliorate obesity and fatty liver. The method involves a step of measuring the inhibitory activity of a candidate substance on a sphingomyelin synthase, wherein the candidate substance is determined to have at least one function selected from the group consisting of an anti-obesity agent, a visceral fat-reducing agent, a fatty liver-treating agent and an adiponectin expression enhancer when the candidate substance has an inhibitory activity on the sphingomyelin synthase.

摘要翻译： 本发明公开了一种能够降低体重的药剂的筛选方法，能够减少内脏脂肪的药剂，能够减少肝脏中的甘油三酯的药剂，以及能够改善肥胖和脂肪肝的药剂 。 该方法包括测定候选物质对鞘磷脂合成酶的抑制活性的步骤，其中所述候选物质被确定为具有至少一种选自抗肥胖剂，内脏脂肪减少剂， 脂肪肝处理剂和脂联素表达增强剂，当候选物质对鞘磷脂合成酶具有抑制活性时。

公开(公告)号：US08889648B2

公开(公告)日：2014-11-18

申请号：US13821536

申请日：2011-09-21

申请人： Susumu Mitsutake ,  Kota Zama ,  Yasuyuki Igarashi ,  Tetsuya Yoshida ,  Yoshikazu Tanaka ,  Hiroshi Takemoto

发明人： Susumu Mitsutake ,  Kota Zama ,  Yasuyuki Igarashi ,  Tetsuya Yoshida ,  Yoshikazu Tanaka ,  Hiroshi Takemoto

IPC分类号： C12N15/113

CPC分类号： C12N15/1137 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/3231 ,  C12Y207/08

摘要： The problem of the present invention is to prove a medicament for decreasing body weigh, a medicament for decreasing visceral fat, a medicament for decreasing triglyceride in the liver, and a method for screening a medicament for ameliorating obesity and fatty liver. The problem is solved by a method comprising measuring an activity of a candidate material for inhibiting a sphingomyelin synthetase wherein if the candidate material has an activity for inhibiting a sphingomyelin synthetase, the candidate material is judged to have at least one function selected from the consisting of an anti-obesity drug, a drug for decreasing visceral fat, a drug for treating fatty liver and an agent for increasing adiponectin expression.

摘要翻译： 本发明的问题是证明减轻体重的药物，用于降低内脏脂肪的药物，用于降低肝脏中甘油三酯的药物，以及筛选用于改善肥胖症和脂肪肝的药物的方法。 该问题通过包括测定用于抑制鞘磷脂合成酶的候选材料的活性的方法来解决，其中如果候选物质具有抑制鞘磷脂合成酶的活性，则该候选物质被判断为具有至少一种选自以下的功能： 抗肥胖药，用于降低内脏脂肪的药物，用于治疗脂肪肝的药物和用于增加脂联素表达的药剂。